Wednesday, July 8, 2026

Patent directory · USPTO A61K / A61P

Patents matching “CTOR”

756 pharma patents match "CTOR" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 756
Index total 30,257
Page 5 / 32

Quick answer

This filtered view shows 756 pharmaceutical patents matching "CTOR" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

756 results for “CTOR” · 30,257 patents in full index Clear search

  1. US 11773393

    Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Oct 3, 2023 · Expires Sep 28, 2043

    granted
  2. US 11760795

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  3. US 11759531

    Gene therapy vectors for treating heart disease

    Tenaya Therapeutics, Inc. · Granted Sep 19, 2023 · Expires Sep 14, 2043

    granted
  4. US 11753366

    Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibitors

    NIKANG THERAPEUTICS, INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  5. US 11753461

    Optimized factor VIII genes

    BIOVERATIV THERAPEUTICS INC. · Granted Sep 12, 2023 · Expires Sep 7, 2043

    granted
  6. US 11739309

    CRISPR-Cas12J effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Aug 29, 2023 · Expires Aug 24, 2043

    granted
  7. US 11732265

    Compositions and methods for modulating complement factor B expression

    Ionis Pharmaceuticals, Inc. · Granted Aug 22, 2023 · Expires Aug 17, 2043

    granted
  8. US 11707536

    Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A

    Takeda Pharmaceutical Company Limited · Granted Jul 25, 2023 · Expires Jul 20, 2043

    granted
  9. US 11690898

    Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 4, 2023 · Expires Jun 29, 2043

    granted
  10. US 11685909

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  11. US 11685771

    Recombinant factor VIII proteins

    BIOVERATIV THERAPEUTICS INC. · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  12. US 11685775

    Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

    The Regents of the University of California · Granted Jun 27, 2023 · Expires Jun 22, 2043

    granted
  13. US 11642398

    Factor IX polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Granted May 9, 2023 · Expires May 4, 2043

    granted
  14. US 11643394

    Krüppel-like factor 15 (KLF15) small molecule agonists in kidney disease

    United States Government as represented by the Department of Veterans Affairs · Granted May 9, 2023 · Expires May 4, 2043

    granted
  15. US 11638753

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Granted May 2, 2023 · Expires Apr 27, 2043

    granted
  16. US 11634482

    Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer

    Julius-Maximilians-Universitat Wurzburg · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted
  17. US 11628205

    Conjugates of a factor VIII moiety having an oxime-containing linkage

    Nektar Therapeutics · Granted Apr 18, 2023 · Expires Apr 13, 2043

    granted
  18. US 11617801

    RP2 and RPGR vectors for treating X-linked retinitis pigmentosa

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 4, 2023 · Expires Mar 30, 2043

    granted
  19. US 11612652

    Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy

    PDS Biotechnology Corporation · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted
  20. US 11596671

    Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Mar 7, 2023 · Expires Mar 2, 2043

    granted
  21. US 11591613

    Retroviral and lentiviral vectors

    AUTOLUS LIMITED · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted
  22. US 11578135

    Multispecific antigen-binding molecules binding to a target and an internalizing effector protein that is CD63 and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  23. US 11578313

    CRISPR-Cas effector polypeptides and methods of use thereof

    The Regents of the University of California · Granted Feb 14, 2023 · Expires Feb 9, 2043

    granted
  24. US 11555057

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    The Regents of the University of California · Granted Jan 17, 2023 · Expires Jan 12, 2043

    granted